Johnson & Johnson is trading 3.36% higher at €235.00, with no clear catalyst identified.
- The company announced rheumatology presentations and clinical data for an upcoming conference on October 22; its release did not link the news to the stock move.
- Broader markets were lower amid oil-supply and geopolitical concerns, which do not explain the upward move.